Evidence map›Paper›PMID 24364021›Full record

ReviewWorld journal of clinical cases2013

Renal cell carcinoma: Evolving and emerging subtypes.

Suzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of clinical cases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC).International journal of molecular sciences · 2021
    Review
  3. Article
  4. Review
  5. Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Article
  6. Article
  7. Article
  8. Article
  9. Clear cell papillary renal cell carcinoma: a review.International journal of clinical and experimental pathology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Suzanne M CrumleySuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Mukul DivatiaSuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Luan TruongSuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Steven ShenSuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Alberto G AyalaSuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Jae Y RoSuzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States.
Cornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our knowledge of renal cell carcinoma (RCC) is rapidly expanding. For those who diagnose and treat RCC, it is important to understand the new developments. In recent years, many new renal tumors have been described and defined, and our understanding of the biology and clinical correlates of these tumors is changing. Evolving concepts in Xp11 translocation carcinoma, mucinous tubular and spindle cell carcinoma, multilocular cystic clear cell RCC, and carcinoma associated with neuroblastoma are addressed within this review. Tubulocystic carcinoma, thyroid-like follicular carcinoma of kidney, acquired cystic disease-associated RCC, and clear cell papillary RCC are also described. Finally, candidate entities, including RCC with t(6;11) translocation, hybrid oncocytoma/chromophobe RCC, hereditary leiomyomatosis and RCC syndrome, and renal angiomyoadenomatous tumor are reviewed. Knowledge of these new entities is important for diagnosis, treatment and subsequent prognosis. This review provides a targeted summary of new developments in RCC.

Indexed as

11) translocationAcquired cystic kidney diseaseCandidate entitiesCarcinoma associated with neuroblastoma recently described entitiesClear cell papillary renal cell carcinomaHereditary leiomyomatosisMucinous tubular and spindle cellMultilocular cystic clear cellRenal cell carcinomaRenal cell carcinoma with t(6SubtypesXp11 translocation

Identifiers

PMID24364021
PMCPMC3868710
OpenAlexW1582646724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.